A- A A+

Empfehlungen der zweiten Aktualisierung der Leitlinie LONTS. 

Häuser, W., Bock, F., Hüppe, M. et al.

Schmerz 34, 204–244 (2020). doi.org/10.1007/s00482-020-00472-y


Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative. 

Krawczyk N, Bandara S, Merritt S, Shah H, Duncan A, McEntee B, Schiff M, Ahmad NJ, Whaley S, Latimore A, Saloner B. 

Addict Sci Clin Pract. 2022 Jun 2;17(1):30. doi: 10.1186/s13722-022-00313-6. PMID: 35655293; PMCID: PMC9161649.


Integrated care model and point of care diagnostics facilitate Hepatitis C treatment among patients receiving opioid agonist therapy: a retrospective review of medical records. 

Häkkinen, M., Tourunen, J., Pitkänen, T. et al.

Subst Abuse Treat Prev Policy 17, 44 (2022). doi.org/10.1186/s13011-022-00473-3


The iCannTookit: a consensus-based, flexible framework for measuring contemporary cannabis use. 

Lorenzetti, V., Hindocha, C., Petrilli, K., Griffiths, P., Brown, J., Castillo-Carniglia, Á., Caulkins, J.P., Englund, A., El Sohly, M.A., Gage, S.H., Groshkova, T., Gual, A., Hammond, D., Lawn, W., López-Pelayo, H., Manthey, J., Mokrysz, C., Liccardo Pacula, R., van Laar, M., Vandrey, R., Wadsworth, E., Winstock, A., Hall, W., Curran, H.V. and Freeman, T.P. (2022), 

Addiction. doi.org/10.1111/add.15956


USA. Opioids: 4 ways to reduce harm, overdose and death 

Experts share tips for individuals, clinicians and community members to improve how to address substance use disorders and save lives. (University of Michigan, USA. 07.06.2022)


UK. Take Home Naloxone in the UK

Naloxone (provided under the brand names Prenoxad and Nyxoid in the UK) is a medication used to reverse opioid overdose. Since 2015, this medication has been more widely available in the UK as a ‘take home’ emergency medication. (2022)


UK. ACMD Naloxone Review 

The Advisory Council on the Misuse of Drugs has undertaken a review of the availability and implementation of naloxone in the UK. (ACMD, UK, 17.06.2022)


Prävalenz von sexuell und durch Blut übertragenen Infektionen und Tuberkulose bei Menschen in Wohnungslosigkeit in Berlin – Erste Ergebnisse der Pilotstudie POINT

Steffen G und Weber C, Cawley C, Sarma N, Jansen K, Leicht A, Zimmermann R, Kröger S, Kajikhina K, Hövener C, Bremer V (2022):

Epid Bull (13): 25-32 | DOI 10.25646/9856


EMCDDA. EMCDDA launches foresight toolkit for the drugs field 

Analysing potential futures to support decision-making today is increasingly used in a world characterised by rapid, volatile and complex change. More and more organisations, including EU bodies (1), are integrating foresight approaches into their activities. Against this backdrop, the EMCDDA is launching a new online toolkit today to help stakeholders in the drugs field implement their own foresight exercise. (EMCDDA, Lissabon, 23.06.2022)


USA. Naloxone saves Lives

Clinicians play an important role in raising awareness about naloxone. Talk with your patients and their family, friends, and caregivers about the benefits of naloxone. Help reduce the stigma sometimes experienced with its use. (CDC Information and Resource Hub, Juni 2022)


EMCDDA. What is e-health and m-health?

e-Health involves the use of digital technologies to improve health in a variety of ways including:

providing drug-related information with harm reduction advice (e.g. safer use) with or without personalised feedback from professionals and linked with specialised drug services if needed;

treating patients with substance use disorders, including comorbidity, via e-health interventions; educating treatment professionals using e-learning modules on therapeutic techniques; and

using digital diaries to monitor substance use in persons being treated for substance use disorders.

(EMCDDA, Lissabon, 21.06.2022)


Controlling for pleasure and risk: The experiences of sexuality and gender diverse people who use GHB. 

Freestone J, Prestage G, Bourne A, Ezard N, Race K, Nedanoski A, Murray J, Siefried KJ. 

Int J Drug Policy. 2022 Jul;105:103747. doi: 10.1016/j.drugpo.2022.103747. Epub 2022 May 25. PMID: 35643047.


Increased risk of death immediately after discharge from compulsory care for substance abuse. 

Ledberg A, Reitan T. 

Drug Alcohol Depend. 2022 Jul 1;236:109492. doi: 10.1016/j.drugalcdep.2022.109492. Epub 2022 May 10. PMID: 35617775.


Long-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering. 

Fenton JJ, Magnan E, Tseregounis IE, Xing G, Agnoli AL, Tancredi DJ. 

JAMA Netw Open. 2022;5(6):e2216726. doi:10.1001/jamanetworkopen.2022.16726


Analysis of Urine Drug Test Results From Substance Use Disorder Treatment Practices and Overdose Mortality Rates, 2013-2020. 

Whitley P, LaRue L, Fernandez SA, Passik SD, Dawson E, Jackson RD. 

JAMA Netw Open. 2022;5(6):e2215425. doi:10.1001/jamanetworkopen.2022.15425


USA. Challenges in Identifying Novel Psychoactive Substances and a Stronger Path Forward

The importance of non-targeted testing to keep pace with a rapidly evolving synthetic opioid market. (NIJ – National Institute of Justice, USA, 11.06.2022)


Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. 

Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Bruneau J, Fischer B, Rehm J, Wild TC, Wood E, Brissette S, Gagnon L, Fikowski J, Ledjiar O, Masse B, Socias ME; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. 

Am J Psychiatry. 2022 Jun 15:appiajp21090964. doi: 10.1176/appi.ajp.21090964. Epub ahead of print. PMID: 35702828.


Alcohol Consumption Levels and Health Care Utilization in Germany - Results from the GEDA 2014/2015-EHIS Study

Sinclair Carr, Christina Lindemann, Ludwig Kraus, Jürgen Rehm, Bernd Schulte und Jakob Manthey

Online veröffentlicht:June 14, 2022, doi.org/10.1024/0939-5911/a000767


Addiction - Volume 117, Issue 7, Pages: 1825-2127, July 2022


Sucht - Jahrgang 68 - Heft 3 - 2022


Gabapentinoids: repeating mistakes of the past?. 

Murnion, B., Schaffer, A., Cairns, R. and Brett, J. (2022), Addiction. doi.org/10.1111/add.15970


EMCDDA. New psychoactive substances: 25 years of early warning and response in Europe — an update from the EU Early Warning System

This update from the EU Early Warning System overviews the NPS situation in Europe in 2020-2021 and highlights emerging threats to support early warning, preparedness planning and response measures. In addition, it reflects on the changes and the lessons learned from 25 years of monitoring NPS in Europe. (EMCDDA, Lissabon, Juni 2022)


Dead Space in Syringes Explained

A short film explaining the importance of dead space as a factor in the transmission of blood borne viruses amongst people who inject drugs. (exchangesupplies.org, UK, 08.06.2022, Video, 03:49) 


EMCDDA webinar: Drug consumption rooms in Europe (02.06.2022) - Video

Objective: The main objective of this webinar is to provide an overview of the different types of drug consumptions rooms (DCRs) in Europe. It will describe the challenges and current reality, as well as look towards the future and consider how this service could adapt and evolve. (EMCDDA, Lissabon, 09.06.2022, Videom 01:34:49)


Language Matters: Is This a Drug Overdose or Drug Poisoning Crisis?

In public policy, language matters. In drug policy, language has always been divisive. Words from “dealer” to “addict” have been used to marginalise, incarcerate, and strip three-dimensional humanity away from people by casting them as two-dimensional villains. (TalkingDrugs, UK, 09.06.2022)


Setting foot in private spaces: extending the hepatitis C cascade of care to automatic needle/syringe dispensing machines, a mixed methods study. 

Coupland, H., Henderson, C., Pritchard-Jones, J. et al.

Harm Reduct J 19, 56 (2022). doi.org/10.1186/s12954-022-00640-6


Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. 

Barré T, Carrat F, Ramier C, Fontaine H, Di Beo V, Bureau M, Dorival C, Larrey D, Delarocque-Astagneau E, Mathurin P, Marcellin F, Petrov-Sanchez V, Cagnot C, Carrieri P, Pol S, Protopopescu C; ANRS/AFEF Hepather study group. 

J Cannabis Res. 2022 Jun 11;4(1):31. doi: 10.1186/s42238-022-00138-9. PMID: 35690798; PMCID: PMC9188079.


The hepatitis C epidemic in Canada: An overview of recent trends in surveillance, injection drug use, harm reduction and treatment. 

Lourenço L, Kelly M, Tarasuk J, Stairs K, Bryson M, Popovic N, Aho J. 

Can Commun Dis Rep. 2021 Dec 9;47(12):561-570. doi: 10.14745/ccdr.v47i12a01. PMID: 35692566; PMCID: PMC9126177.


Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression

Hosseini-Hooshyar, Samira et al.

The Lancet HIV, Volume 9, Issue 6, e414 - e427